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144Objectives:We sought to estimate the prevalence and identify the predictors of impaired growth after infant car-
diac surgery.
Methods: We performed a secondary analysis of a prospective study of the role of apolipoprotein E gene poly-
morphisms on neurodevelopment in young children after infant cardiac surgery. Prevalence estimates for growth
velocity were derived by using anthropometric measures (weight and head circumference) obtained at birth and at
4 years of age. Genetic evaluation was also performed. Growth measure z scores were calculated by using World
Health Organization Child Growth Standards. Growth velocity was evaluated by using 2 different techniques:
first by clustering the children into one of 3 growth velocity subgroups based on z scores (impaired growth,
difference<0.5 standard deviation; stable growth, difference of0.5 to 0.5 standard deviation; and improving
growth, difference>0.5 SD) and second by using continuous difference scores. Statistical analyses were con-
ducted with a combination of proportional odds models for the ordered categories and simple linear regression
for the continuous outcomes.
Results: Three hundred nineteen full-term subjects had complete anthropometric measures for weight and head
circumference at birth and 4 years. The cohort was 56% male. Genetic examinations were available for 97%
(309/319) of the cohort (normal, 74%; definite or suspected genetic abnormality, 26%). Frequency counts for
weight categories were as follows: impaired growth, 37%; stable growth, 31%; and improving growth, 32%.
Frequency counts for head circumference categories were as follows: impaired growth, 39%; stable growth,
28%; and improving growth, 33%. The presence of a definite or suspected genetic syndrome (P¼ .04) was found
to be a predictor of impaired growth for weight but not for head circumference. When growth z scores were used
as continuous outcomes, the apolipoprotein E e2 allele was found to be predictive of lower z scores for both
weight (P ¼ .02) and head circumference (P ¼ .03).
Conclusions: Impaired growth for both weight and head circumference is common (both>30%) in this cohort of
children after infant cardiac surgery. Both the apolipoprotein E e2 allele and the presence of a definite or suspected
genetic syndrome were associated with impaired weight growth velocity. The apolipoprotein E e2 allele was also
associated with impaired growth velocity for head circumference. Persistent poor growth might have long-term
implications for the health and development of children with congenital heart defects. (J Thorac Cardiovasc Surg
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mal development. Suboptimal growth can lead to decreased
survival and poor cognitive outcomes. Chronic disease statese Divisions of Cardiothoracic Surgerya; Gastroenterology, Hepatology and
tionc; Psychologyd; Geneticse; Pediatricsf; andNeurology,g the Cardiac Center,
hildren’s Hospital of Philadelphia, Philadelphia, Pa, and the Division of Bio-
ics and Epidemiology and the Heart Institute,b Cincinnati Children’s Hospital
cal Center, Cincinnati, Ohio.
ed by a grant from the Fannie E. Rippel Foundation, an American Heart
iation National Grant-in-Aid (9950480N), and grant HL071834 from the
nal Institutes of Health.
res: None.
d for publication May 26, 2009; revisions received Nov 16, 2009; accepted for
ation Jan 10, 2010; available ahead of print April 12, 2010.
for reprints: Nancy Burnham, RN, MSN, CRNP, Division of Cardiothoracic
ry, the Children’s Hospital of Philadelphia, 34th and Civic Center Blvd, Phil-
hia, PA 19104 (E-mail: burnhamn@email.chop.edu).
23/$36.00
ht  2010 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.01.003
The Journal of Thoracic and Cardiovascular Surgincrease the risk of growth impairment. Despite early neona-
tal repair and improved survival of children with congenital
heart defects (CHDs), there is increasing evidence that chil-
dren with CHDs are at an increased risk for both impaired
growth and abnormal neurodevelopment.1-5 Growth impair-
ment in children with CHDs can begin before birth, as indi-
cated by an increased prevalence of intrauterine growth
retardation in several population-based studies.6-8 During
the perioperative period, altered energy intake and energy ex-
penditure result in an ongoing risk of malnutrition.9-14 The
prevalence and cause of growth impairment in the CHD pop-
ulation is poorly understood. Simple cross-sectional analyses
of growth using group means or simple thresholds for ade-
quate growth are relatively insensitive and might fail to iden-
tify many children with impaired growth.15 Assessment of
growth patterns or velocitymight bemore appropriate in chil-
dren with chronic diseases who are at an increased risk forery c July 2010
Abbreviations and Acronyms
APOE ¼ apolipoprotein E
CHD ¼ congenital heart defect
DHCA ¼ deep hypothermic circulatory arrest
HC ¼ head circumference
HCZ ¼ head circumference–for–age z score
SD ¼ standard deviation
TOF ¼ tetralogy of Fallot
VSD ¼ ventricular septal defect
WAZ ¼ weight-for-age z score
WHO ¼ World Health Organization
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growth is important because inadequate nutritional intake
and subsequent poor growth are potentially modifiable fac-
tors. Therapeutic interventions that lead to more optimal
growth might result in improved outcomes.
In 1998, we initiated a prospective study evaluating the
association between neurodevelopmental dysfunction and
apolipoprotein E (APOE) genotype in 550 neonates and in-
fants undergoing operations for CHDs. APOE is an impor-
tant regulator of cholesterol metabolism and has an
important role as a susceptibility gene that modifies outcome
after central nervous system injury. The APOE e2 allele was
associated with significantly worse neurodevelopmental
outcomes at 1 and 4 years of age.19,20 Anthropometric
growth measurements were obtained from labor and deliv-
ery records and at both these evaluations. The current study
was undertaken to estimate the prevalence and identify pre-
dictors of impaired growth from birth to 4 years of age after
infant cardiac surgery.MATERIALS AND METHODS
Study Population
The study constitutes a secondary analysis of a subgroup of a prospective
study of the role of APOE gene polymorphisms on neurodevelopment after
cardiac surgery in infancy.19,21 Patients 6 months of age or younger under-
going surgical intervention for CHDs with cardiopulmonary bypass with or
without deep hypothermic circulatory arrest (DHCA) were eligible. Exclu-
sion criteria were as follows: (1) multiple congenital anomalies, (2) recog-
nizable genetic or phenotypic syndrome other than chromosome 22q11
microdeletion syndrome, and (3) language other than English spoken in
the home. Patients underwent neurodevelopmental assessments at 1 and 4
years of age. The current study evaluated full-term infants (gestational
age, 37 weeks) for whom complete birth and 4-year data on relevant an-
thropometric measures were available. Premature infants were excluded be-
cause the World Health Organization (WHO) growth chart normative data
does not include premature infants. The study was approved by the Institu-
tional Review Board at the Children’s Hospital of Philadelphia. Informed
consent was obtained from the parent or guardian.
Operative Management
Surgical intervention was performed by 5 cardiac surgeons with a dedi-
cated team of cardiac anesthesiologists. Alpha-stat blood gas managementThe Journal of Thoracic and Cawas used. Pump flow rates were not standardized for this study. DHCA
was used at the surgeon’s discretion. Before DHCA, patients underwent
core cooling, with topical hypothermia of the head, to a nasopharyngeal
temperature of 18C. Modified ultrafiltration was performed in all patients.
Anthropometric Measurement and Growth
Assessment
Anthropometric measurements (weight and head circumference [HC]]
were obtained at birth and at a 4-year follow-up. Of note, both length and
height were obtained at birth and the 4-year follow-up; however, the birth
length measurement was considered not sufficiently accurate to use for an
analysis in which the focus was on patterns of growth after cardiac surgery.
Birth measurements were collected from labor and delivery records. Mea-
surements at the 4-year follow-up were obtained by research nurses using
standardized research protocols with digital scales and stadiometers.
Weight-for-age z scores (WAZs) and HC-for-age z scores (HCZs) were cal-
culated by using the WHO Child Growth Standards. The WHO Growth
Standards were released in 2006 and are based on prospectively collected
data from a population of ethnically diverse, singleton, term-born infants
who were primarily breast-fed. This population was selected to represent
optimal growth (ie, ‘‘how children should grow’’).22 Use of the WHO
standards provides adjustment for growth differences caused by sex and
ethnicity.
Genetic Evaluations
Patients were evaluated at the 1-year evaluation, 4-year evaluation, or
both by a genetic dysmorphologist. Chromosome analysis and testing for
microdeletion of 22q11 were performed as indicated. Results of the genetic
evaluations were classified as normal if no genetic or chromosomal abnor-
mality was demonstrated, abnormal if a specific diagnosis was confirmed,
and suspect if there was evidence of a genetic syndrome that could not be
confirmed. For the analysis, the abnormal and suspect subgroups were com-
bined.
APOE Genotype Determination
Whole blood or a buccal swab was obtained before the operation and
stored at 4C. Genomic DNA was prepared and used to determine APOE
genotypes by using a previously published method. Subjects were grouped
by APOE genotype into the e2 group (e2e2 and e3e2), the e3 group (e3e3),
and the e4 group (e3e4 and e4e4). The e2e4 subjects were excluded from the
analyses because the e2 and e4 alleles are in opposition in their effects in
some conditions, such as Alzheimer’s disease.19
Cardiac Diagnosis
Cardiac diagnosis was coded according to a previously described classi-
fication incorporating anatomy and perioperative physiology that has been
shown to be predictive of perioperative mortality.23 Class I is 2 ventricles
with no aortic arch obstruction, class II is 2 ventricles with aortic arch ob-
struction, class III is a single ventricle with no arch obstruction, and class
IV is a single ventricle with arch obstruction. Patients with tetralogy of Fal-
lot (TOF) and transposition of the great arteries are in class I, whereas pa-
tients with hypoplastic left heart syndrome or variants are in class IV.
Data Analysis and Statistical Methods
Data analysis proceeded in 3 discrete phases. First was a descriptive
phase in which traditional descriptive statistics were computed for all vari-
ables in the data set, with a particular emphasis on growth status at birth and
4 years of age. Second and third were 2 separate prevalence phases, in which
prevalence estimates for impaired growth were computed by using 2 differ-
ent criteria: (1) a simple cross-sectional evaluation with a cutoff of2 stan-
dard deviations (SDs) for weight and HC z scores at 4 years of age and (2) by
using an estimate of growth velocity from birth to 4 years (z scores atrdiovascular Surgery c Volume 140, Number 1 145
TABLE 1. Baseline and operative characteristics
Entire
group
Impaired
growth
Stable
growth
Improving
growth
No. 319 117 (37%) 100 (31%) 102 (32%)
Sex
Female 139 (44%) 47 (40%) 53 (53%) 39 (38%)
Male 180 (56%) 70 (60%) 47 (47%) 63 (62%)
Ethnicity
Asian–Pacific,
Hispanic, other
34 (11%) 13 (11%) 12 (12%) 9 (9%)
African American 68 (21%) 16 (14%) 20 (20%) 32 (31%)
White 217 (68%) 88 (75%) 68 (68%) 61 (60%)
Diagnostic class
I: 2 ventricles/no
arch obstruction
163 (51%) 53 (46%) 51 (51%) 59 (58%)
II: 2 ventricles/arch
obstruction
43 (14%) 12 (10%) 18 (18%) 13 (13%)
III: 1 ventricle/no
arch obstruction
29 (9%) 12 (10%) 5 (5%) 12 (12%)
IV: 1 ventricle/arch
obstruction
84 (26%) 40 (34%) 26 (26%) 18 (17%)
Genetic evaluation
Normal 237 (74%) 78 (67%) 79 (79%) 80 (78%)
Yes 82 (26%) 39 (33%) 21 (21%) 22 (22%)
APOE genotype
e2 30 (10%) 15 (13%) 9 (9%) 6 (6%)
e3 187 (60%) 63 (55%) 57 (60%) 67 (67%)
e4 92 (30%) 36 (32%) 29 (31%) 27 (27%)
Missing 10 3 5 2
DHCA at first operation
No 135 (42%) 41 (35%) 43 (43%) 51 (50%)
Yes 184 (58%) 76 (65%) 57 (57%) 51 (50%)
Additional operations
before 4-y evaluation
None 189 (59%) 60 (51%) 63 (63%) 66 (65%)
1–2 122 (38%) 55 (47%) 35 (35%) 32 (31%)
>2 8 (3%) 2 (2%) 2 (2%) 4 (4%)
APOE, Apolipoprotein E; DHCA, deep hypothermic circulatory arrest.
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dividing the z score difference values into 3 different velocity subgroups:
impaired growth, difference less than0.5 SD; stable growth, difference
of0.5 SD to 0.5 SD; and improving growth, difference greater than 0.5
SD. The importance of using both criteria is that the cross-sectional evalu-
ation with a2 SD threshold is a traditional screening criterion for growth
failure in healthy populations. Use of growth velocities allows evaluation
of the pattern and tempo of growth and will identify those children who
have deviated substantially from their individual growth trajectories.
In the risk-modeling phase, a total of 14 separate single-covariate, pro-
portional-odds, growth failure models were specified and tested by using
the 3 velocity subgroups as the outcome and a selected set of patient-specific
and perioperative variables as the testable covariates. Finally, 4 single-cova-
riate linear regression models were also tested in which the original contin-
uous measure of velocity (z score at birthz score at 4 years) served as the
outcome and genotype and duration of DHCA at the first operation were
used as the testable covariates. In an effort to rule out the possibility of re-
dundancy among predictors, the relationship between duration of DHCA
and cardiac diagnosis was estimated by using a Spearman rho correlation
coefficient. Because of the exploratory nature of the study, a was not146 The Journal of Thoracic and Cardiovascular Surgadjusted beyond the traditional a level of 0.05. All data were analyzed
with SAS version 9.1 software (SAS Institute, Inc, Cary, Inc).
RESULTS
Between September 1998 and April 2003, 675 eligible in-
fants underwent cardiac surgery. Twenty-three infants died
before consent, parents of 102 declined participation, and
550 (81%) were enrolled. There were 21 deaths during the
initial hospitalization and an additional 43 before 5 years
of age. Four hundred eighty-six patients were alive and eli-
gible for the 4-year evaluation, which was completed by 381
patients (78% of the eligible population). Baseline charac-
teristics have been previously reported for patients returning
for the 4-year evaluation (n¼ 381), those who did not return
(n ¼ 105), and those who died before age 4 years (n ¼ 64).
The only significant difference in baseline characteristics be-
tween returning and nonreturning patients was underrepre-
sentation of African Americans among the returning
patients (21% vs 29%). Three hundred nineteen patients
met the entry criteria for the current study. Baseline charac-
teristics are shown in Table 1.
Prevalence of Impaired Growth
Cross-sectional evaluation. The mean WAZs at birth and
4 years of age were0.14 ( 1.12) and 0.21 ( 1.17), re-
spectively. The mean HCZs at birth and 4 years were
0.19 ( 1.37) and0.28 ( 1.22), respectively. The preva-
lence of impaired growth as assessed by a WAZ of less than
2.0 was 5% at birth and 6% at 4 years. The prevalence of
impaired growth as assessed by an HCZ of less than2.0 at
birth was 9% at birth and 8% at 4 years.
Growth velocity. Frequency counts for growth velocity
groups for weight were as follows: impaired growth, 37%
(117/319); stable growth, 31% (100/319); and improving
growth, 32% (102/319). Frequency counts for growth ve-
locity subgroups for HC were as follows: impaired growth,
39% (126/319); stable growth, 28% (88/319); and improv-
ing growth, 33% (105/319).
Risk models
Weight growth velocity categories. The presence of a def-
inite or suspected genetic syndrome was a predictor of im-
paired growth for weight (P ¼ .04, Table 2). Longer
duration of DHCAwas also associated with impaired weight
growth (P¼ .02). Duration of DHCA was related to the car-
diac diagnosis (r¼ 0.57, P<.001). Use and longer duration
of DHCA were more common in class IV patients. Overall,
cardiac diagnosis was not associated with weight growth.
However, growth impairment for weight was more common
in class IV patients compared with class I patients (P¼ .01).
APOE genotype was not associated with weight growth.
HC growth velocity categories. Presence of a definite or
suspected genetic syndrome, longer duration of DHCA,
and cardiac diagnosis were not predictive of HC growthery c July 2010
TABLE 2. Risk models for weight growth velocity categories (logistic
regression)
Parameter Estimate Standard error P value
Confirmed or suspected
genetic anomaly
0.242 0.121 .045
Diagnostic class .060
Class II vs class I 0.163 0.235 .489
Class III vs class I 0.110 0.273 .674
Class IV vs class I 0.475 0.193 .014
APOE genotype .12
APOE e2 vs APOE e3 0.392 0.244 .107
APOE e4 vs APOE e3 0.064 0.178 .718
CPB duration, first Operation 0.001 0.003 .629
Duration of additional CPB 0.002 0.002 .238
DHCA duration, first operation 0.011 0.005 .017
Duration of additional DHCA 0.005 0.004 .284
The statistically significant parameters are in bold. APOE, Apolipoprotein E;CPB, car-
diopulmonary bypass; DHCA, deep hypothermic circulatory arrest.
TABLE 3. Risk models for head circumference growth velocity
categories (logistic regression)
Parameter Estimate Standard error P value
Confirmed or suspected
genetic anomaly
0.095 0.120 .430
Diagnostic class .40
Class II vs class I 0.269 0.239 .260
Class III vs class I 0.250 0.274 .361
Class IV vs class I -0.138 0.192 .471
APOE genotype .099
APOE e2 vs APOE e3 -0.519 0.249 .037
APOE e4 vs APOE e3 0.224 0.180 .213
CPB duration, first operation 0.001 0.003 .581
Duration of additional CPB 0.001 0.002 .493
DHCA duration, first operation 0.008 0.005 .092
Duration of additional DHCA 0.002 0.004 .648
The statistically significant parameters are in bold. APOE, Apolipoprotein E;CPB, car-
diopulmonary bypass; DHCA, deep hypothermic circulatory arrest.
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HC growth. However, growth impairment for HC was more
common in patients with the APOE e2 allele compared with
those with the e3 allele (P ¼ .037).
Growth velocities as continuous outcomes. The APOE e2
allele was predictive of lower growth velocity for both
weight (P ¼ .02) and HC (P ¼ .03). Longer duration of
DHCA at the first operation was also associated with lower
growth velocity for both weight (P¼ .01) and HC (P¼ .02).
However, the r2 value for both was approximately 0.02, sug-
gesting that most of the variance for both weight and HC, up
to 98%, is not explained by these factors.
DISCUSSION
Growth patterns provide an important window into the
overall well-being of healthy children and those with chronic
diseases. In this study we show that growth impairment or
faltering assessed as a decreasing growth velocity between
birth and 4 years for both weight and HC is common (both
>30%) after infant cardiac surgery. Evaluation of growth
with more traditional criteria, such as group means, or use
of cross-sectional assessment with a simple threshold was
relatively insensitive and suggested a much lower preva-
lence of growth impairment (6% to 8%). Use of growth ve-
locities identifies subnormal weight or HC rate of gain rather
than merely subnormal weight or HC.15 Defining growth im-
pairment as decreasing to less than a predetermined percen-
tile or z score is only an estimate of attained weight and not
an estimate of growth because it will not identify children
who fall from a high percentile or z score. Use of the growth
velocities shows that children with CHDs are a heteroge-
neous population with differing patterns of growth. In addi-
tion to the impaired growth subgroup, there is a group with
improving or increasing growth velocity. Although some of
these children might be exhibiting ‘‘catch-up’’ growth,
others might be at risk for childhood obesity.The Journal of Thoracic and CaIn the current study we identified that both the APOE e2
allele and the presence of a definite or suspected genetic syn-
drome were associated with impaired weight growth veloc-
ity. The APOE e2 allele was also associated with impaired
growth velocity for HC. In addition, longer duration of
DHCA at the initial operation was associated with impaired
growth, as assessed based on body weight. However, taken
in combination, these factors explain only a very small por-
tion (<2%) of the variability in growth for both weight and
HC. No other factors were found to be predictive of either
impaired or improving growth.
The large group of patients with impaired HC growth is
particularly concerning. Neurodevelopmental dysfunction
is now the most common and potentially disabling long-
term complication of CHD and its treatment. Infancy and
early childhood are critical periods for brain growth. Early
postnatal malnutrition is associated with significantly re-
tarded central nervous system growth, reduced brain weight,
thinner cerebral cortex, and deficient myelinization.24 The
adverse effects of malnutrition on neurodevelopmental out-
comes have been well described in other populations. Inad-
equate nutritional intake and subsequent poor growth are
potentially modifiable factors. Early identification of
patients at risk for poor growth could lead to therapeutic
interventions, more optimal growth, and improved neurode-
velopmental outcomes.
Impaired growth has long been recognized as a significant
problem in children with CHDs. In 1962, Mehrizi and
Drash25 called attention to the common occurrence of
growth disturbances in children with a wide variety of
CHDs. Levy and associates1 evaluated growth in patients
with ventricular septal defects (VSDs) enrolled in the Joint
Study on the Natural History of Congenital Heart Defects.
Successful surgical intervention resulted in a significant in-
crease in weight but not height. Medical therapy was associ-
ated with little change in the subnormal growth pattern. Theyrdiovascular Surgery c Volume 140, Number 1 147
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with VSDs is only in part caused by abnormal postnatal he-
modynamics. Intrauterine and genetic factors and low birth
weight were identified as risk factors and might explain
the incomplete growth response after successful surgical in-
tervention. A subsequent study of long-term growth of chil-
dren with CHDs showed that growth in children with a large
VSD or TOF was abnormal. Growth improved but did not
normalize after surgical intervention.4 More recently,
Cheung and colleagues26 demonstrated normalization of
long-term growth after repair of TOF. There has been in-
creased interest in growth patterns for patients with single-
ventricle anatomy and physiology. Cohen and coworkers27
found that children with functionally univentricular hearts
who have been palliated with a Fontan operation are signif-
icantly underweight and shorter than the general population
and their siblings. In a more recent study, Vogt and associ-
ates28 found that impaired growth is common in children
with single-ventricle physiology before completion of the
superior cavopulmonary connection and that some catch-
up growth occurred subsequently. However, even after the
Fontan procedure, the median WAZ remained decreased at
0.7. The findings of these studies are consistent with the
current study in identification of more complex CHDs and
genetic factors as important risk factors for growth distur-
bance. Unlike the current study, these studies used group
means to estimate the prevalence of growth failure. The cur-
rent study demonstrates that group means and screening
thresholds are insensitive measures that fail to identify
many children with impaired growth.
The cause of growth failure in patients with CHDs is mul-
tifactorial and most likely includes a hypermetabolic state,
inadequate caloric intake, malabsorption, genetic factors,
or a consequence of fluid restriction as part of hemodynamic
intervention.10-13 Inadequate caloric intake is probably a ma-
jor contributor to growth failure in neonates who require car-
diac surgery.13 Feeding difficulties are common in this
population and might be due to congestive heart failure, vo-
cal cord paresis, uncoordinated sucking and swallowing, fa-
tigue, or feeding aversion.12 In addition, digestion and
absorption in the gastrointestinal tract can be impaired by
gut edema. Patients with single-ventricle physiology and
an aortopulmonary shunt might have relative splanchnic is-
chemia caused by diastolic runoff from the shunt and are at
increased risk for necrotizing enterocolitis.13
APOE polymorphisms might have different roles during
early development and aging.29,30 In adults the APOE e4 al-
lele is associated with a risk of Alzheimer’s disease and
worse outcome after traumatic brain injury.31 However,
there is evidence that infants with the APOE e4 allele might
have advantages over those with the APOE e2 and e3 alleles
with respect to early-life neuronal and brain development.32
We have shown that the APOE e2 allele was associated with
significantly worse neurodevelopmental outcomes at 1 and 4148 The Journal of Thoracic and Cardiovascular Surgyears of age.19,20 In the current study we found that the
APOE e2 allele is also associated with a risk of impaired
weight and HC growth. In addition, there is evidence that
early cognitive development under the stresses of environ-
mental factors, such as malnutrition and lead exposure,
might be modulated by APOE genotype.29,30,32 As in the
current study, the APOE e2 allele is associated with worse
outcomes, whereas the APOE e4 allele is protective. This
finding is consistent with the concept of thrifty genotypes
and thrifty phenotype, metabolic adaptations adopted as sur-
vival strategies by a malnourished fetus or infant that might
be inappropriate to deal with a later life of affluence.33 The
APOE e4 allele is a more lipid-thrifty variant that is more ef-
ficient in sequestering cholesterol and increasing serum lipid
levels, which might have a critical role for brain develop-
ment and maturation.29,30,33 Although this phenomenon
might be advantageous in an infant with marginal nutrition,
it is associated with hyperlipidemia and coronary artery dis-
ease in adults.31
There are several limitations to this study. The birth data
were collected from delivery room records, and thus mea-
surements might not have been made in a standard fashion.
Anthropometric data are available for only 2 time points. We
did not collect parental anthropometric data to determine
whether a small child is constitutionally small. However,
use of growth velocity obviates some of this problem be-
cause a child who is small and has a decrease of 0.5 z score
still exhibits poor growth. Finally, regression to the mean
must always be considered as a potential influence when
multiple measures are obtained over time. Yet regression
to the mean is generally symmetric and is as likely to happen
for low-scoring children as it is for high-scoring children.
Even in the presence of regression to the mean, however,
children tend to remain around their expectation (ie, their ex-
pected levels of performance), with some fluctuation both
ways. Hence fluctuation associated with regression to the
mean is not unidirectional. In the current sample of children
undergoing operations for heart disease, we simply do not
see the same proportion of children at the high ends of the
distributions that we saw at the low ends, especially with re-
spect to growth failure. We do, however, have a fairly high
number of infants who scored low initially and then re-
mained ‘‘within their growth channel’’ relative to the
WHO standards at birth and 4 years of age.
In summary, impaired weight and HC growth, as assessed
by decreasing growth velocities, is common after cardiac
surgery in infancy. The significant prevalence of impaired
head growth is particularly concerning because of the impli-
cations for neurodevelopmental outcomes. Growth veloci-
ties are more appropriate and sensitive measures of growth
patterns than simple cross-sectional evaluations. Genetic
factors are important determinants of impaired growth.
However, the risk factors identified in this study explain
only a small portion of the variability in outcomes,ery c July 2010
Burnham et al Congenital Heart Diseasesuggesting that many thus far unidentified factors likely con-
tribute to the risk of poor growth. Nutritional support of chil-
dren with CHDs is a modifiable factor. Early identification
of patients at risk for poor growth could lead to therapeutic
interventions, more optimal growth, and improved neurode-
velopmental outcomes. Further research is needed to assess
risk factors for poor growth, evaluate the effect of poor
growth on neurodevelopmental outcomes, and determine
the role for therapies to improve nutrition and growth.C
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